demonstrated significant tumor growth inhibition in BRAF inhibitor (BRAFi)-resistant colorectal cancer when FAK inhibitors (FAKi) were combined with RAF/MEK inhibitors (RAFi/MEKi). Here, PTK2 is linked to neoplasm.